NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy MDGL

*Your capital is at risk

$467.32

-25.79 (-5.23%)

At Close: Jul 31, 2026

Madrigal Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -22.27. In total, the insiders bought 224.94K and sold 42.5K MDGL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-22.27
● Buy	224.94K shares
● Sell	42.5K shares
35% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jul 17, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -22.27. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	2 238 Value: $1.10M
Jan 20, 2026 Sell	Common Stock S-Sale	Kelley Shannon T General Counsel	Officer	429 Value: $215.1K
Jan 15, 2026 Buy	Common Stock A-Award	Thakkar Rita Chief Accounting Officer	Officer	2 398 Value: $1.19M
Jan 15, 2026 Buy	Stock Option (Right to Buy) A-Award	Thakkar Rita Chief Accounting Officer	Officer	1 826 Value: $905.5K
Jan 12, 2026 Buy	Common Stock J-Other	Thakkar Rita Officer	Officer	0 Value: $0
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	846 Value: $439.8K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	2 450 Value: $1.27M
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	766 Value: $395.9K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	681 Value: $354.8K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	970 Value: $507.3K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	2 432 Value: $1.28M
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 066 Value: $560.7K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	575 Value: $303.7K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 094 Value: $561.3K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 480 Value: $757.7K
Jan 09, 2026 Buy	Common Stock M-Exempt	Friedman Paul A Director	Director	24 520 Value: $387.4K
Jan 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Friedman Paul A Director	Director	280 Value: $4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	280 Value: $154.3K
Jan 09, 2026 Buy	Common Stock M-Exempt	Friedman Paul A Director	Director	280 Value: $4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	691 Value: $365.7K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 560 Value: $822.1K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 199 Value: $628.4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	840 Value: $438.5K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 345 Value: $692.2K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 996 Value: $1.03M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,...

Read Full Profile Here